Osteochin (Quinoin, Hungary) efficacy was studied in the treatment of 20 patients with Duchenne's progressive myodystrophy. The drug was administered in a dose of 200 mg a day for a month. A favorable effect of such therapy was observed in all the patients. Osteochin was found to have a correcting effect on Ca-regulating hormone function and to promote stabilization of the myodystrophic process.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
[Place of ipriflavone in the therapy of osteoporosis].
Acta Pharm Hung
November 1995
Chinoin Gyógyszer-és Vegyészeti Termékek Gyára Rt, Budapest.
In Hungary ipriflavone has been marketed under the name Osteochin. After a short summary of the clinically proven results the article tries to position ipriflavone among antiosteoporotic drugs. Not only on the basis of preclinical results the article shows that Osteochin--as a non hormonal agent--can be given to those patients who can not receive hormone replacement therapy, there are grounds for giving combination of ipriflavone and a low dose estrogen.
View Article and Find Full Text PDF[The effect of osteochin on the dynamics of the course of the myodystrophic process].
Zh Nevropatol Psikhiatr Im S S Korsakova
December 1992
Osteochin (Quinoin, Hungary) efficacy was studied in the treatment of 20 patients with Duchenne's progressive myodystrophy. The drug was administered in a dose of 200 mg a day for a month. A favorable effect of such therapy was observed in all the patients.
View Article and Find Full Text PDF[A new treatment possibility for osteoporosis with osteochin (ipriflavone) tablets].
Magy Traumatol Orthop Helyreallito Seb
October 1989
It was found as a result of preclinical experimental examinations, performed in Hungary and Japan that Ipriflavone stimulates calcitonin secretion through increasing the oestrogene effect. Its effect of hindering bone resorption works presumably also this way. Authors report on experiences and results gained in 408 treatment years of 114 primary and secondary osteoporotic patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!